Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 18:10 ET | Source: Bragar Eagel & Squire

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Altimmune’s MASH drug trial missed its main fibrosis goal due to high placebo response; after results on June 26, 2025, shares fell 53% in one day.
October 06, 2025 10:09 ET | Source: Bragar Eagel & Squire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Altimmune allegedly misled investors on Pemvidutide’s MASH trial, which failed its key fibrosis endpoint, causing shares to plunge 53% on June 26, 2025.
October 05, 2025 23:40 ET | Source: Faruqi & Faruqi LLP

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or...
October 03, 2025 20:02 ET | Source: The Rosen Law Firm PA

ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important October 6 Deadline in Securities Class Action – ALT

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and...
October 03, 2025 11:06 ET | Source: Bragar Eagel & Squire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

Altimmune allegedly failed to achieve statistical significance in its Phase 2b MASH trial; stock dropped 53.2% to $3.61 on June 26, 2025.
September 30, 2025 15:27 ET | Source: The Rosen Law Firm PA

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and...
September 30, 2025 15:24 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that...
September 30, 2025 10:20 ET | Source: Faruqi & Faruqi LLP

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered...
September 30, 2025 09:42 ET | Source: Berger Montague

DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the...
September 29, 2025 17:22 ET | Source: Bragar Eagel & Squire

ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit

Altimmune allegedly misled investors; Phase 2b Pemvidutide trial failed primary endpoint, causing shares to plunge 53% on June 26, 2025.